On August 10, 2026, the White House issued an Executive Order establishing what it calls "Gold Standard Childhood Vaccine Recommendations," restructuring federal childhood immunization guidance in the United States. The order follows a December 2025 Presidential Memorandum and May 2026 Executive Order and comes after implementation of earlier vaccine directives was delayed by litigation over the composition of the Advisory Committee on Immunization Practices (ACIP) and separate changes to the federal vaccine schedule.
What it covers
The order divides childhood immunizations into three categories. Vaccines recommended for all children cover 11 diseases: measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, HPV, and varicella. A second category covers certain high-risk groups and populations, including RSV monoclonal antibodies, hepatitis A and B, meningococcal B and ACWY vaccines, and dengue. A third shared clinical decision-making category includes hepatitis A and B, rotavirus, meningococcal disease, influenza, and COVID-19.
The order also states that measles / mumps / rubella (MMR) vaccines should be administered as three separate single-disease vaccines once such products become domestically available and that childhood immunizations should, to the maximum extent feasible, be administered at separate medical visits. Combination vaccines would remain available.
Single-antigen measles, mumps, and rubella vaccines were previously available in the US, including Merck's Attenuvax, Mumpsvax, and Meruvax II, but the products were discontinued around 2009–2010 as combination MMR vaccination became standard. No standalone measles, mumps, or rubella vaccines are currently licensed and routinely available in the US, leaving the administration's proposed separation of MMR without an existing domestic commercial supply. The Executive Order directs HHS to develop plans within 90 days to make single-antigen options available, including through collaboration with manufacturers and, where appropriate, other countries.
The order also advises states and territories to review their immunization requirements, including those governing school enrollment. Separately, the Attorney General is directed to support legal challenges to state laws where the administration considers them inconsistent with federal or constitutional obligations concerning parental authority, religious freedom, disability accommodations, or equal protection. The Departments of Justice, Education, and HHS are directed to ensure that contractors and grantees comply with those obligations.
Why it matters
The action represents a substantial change in federal vaccine policy by moving several widely used childhood immunizations outside the category recommended universally for children. It also departs from established US vaccination practice and has drawn opposition from medical and public health groups. Critics say there is no established safety benefit from separating MMR into individual vaccines or routinely spacing childhood immunizations across additional visits, while warning that additional appointments could create barriers to completing vaccination.
The proposed move toward separate MMR vaccines also creates a development and manufacturing challenge. No single-antigen measles, mumps, or rubella vaccines are currently available in the US, meaning implementation would require new supply sources or development activity. The order directs HHS to work with the private sector and other countries as appropriate, with further plans due within 90 days.